{"gene":"PF3D7_1356900","run_date":"2026-09-08T14:19:06","timeline":{"discoveries":[{"year":1994,"finding":"PK5 (PfPK5) expressed in E. coli as a recombinant protein displays kinase activity against casein and histone H1 substrates. Western blotting with polyclonal antibody showed the kinase is located in the parasite cytosol and is present in approximately constant amounts throughout the intra-erythrocytic asexual reproductive stage.","method":"Recombinant protein expression in E. coli, in vitro kinase assay, Western blotting, subcellular fractionation","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — in vitro kinase assay and localization established in a single study with no replication","pmids":["8143724"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":1994,"finding":"PK5 (PfPK5) failed to complement cdc2/cdc28 yeast mutants, though the gene was not expressed in yeast, leaving open the question of functional equivalence to cdc2.","method":"Yeast complementation assay","journal":"European journal of biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — negative complementation result, single study, confounded by lack of expression in yeast","pmids":["8143724"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":1996,"finding":"PK5 (PfPK5) immunoprecipitated from aphidicolin-blocked parasites shows elevated kinase activity, suggesting involvement in S-phase regulation. Treatment of parasite cultures with CDK inhibitors flavopiridol and olomoucine (which inhibit PfPK5 in vitro at concentrations similar to other CDKs) markedly inhibited DNA synthesis during nuclear division cycles. Immunolocalization provided further evidence for a role in S-phase.","method":"Immunoprecipitation kinase assay from stage-specific parasites, cell-cycle inhibitor treatment, immunolocalization","journal":"Molecular and biochemical parasitology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — multiple methods in single study but indirect pathway placement via pharmacological inhibitors","pmids":["8943149"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2000,"finding":"PK5 (PfPK5) is efficiently activated in vitro by heterologous human cyclin H and p25 (a cyclin-like molecule that activates human CDK5), but is neither activated nor phosphorylated by Pfmrk (the putative P. falciparum CDK-activating kinase). PfPK5 can autophosphorylate in the presence of a cyclin. A novel P. falciparum cyclin homologue, Pfcyc-1, activates recombinant PfPK5 in vitro with efficiency similar to human cyclin H and p25. Activated PfPK5 can be inhibited by chemical CDK inhibitors.","method":"In vitro kinase activation assays with recombinant proteins, autophosphorylation assay, chemical inhibition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro activation with multiple partner proteins, autophosphorylation assay, negative result for Pfmrk, multiple orthogonal approaches in single study","pmids":["10722743"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2001,"finding":"PK5 (PfPK5) is inhibited by heterologous human p21(CIP1) in vitro, but is not inhibited by the CDK4/6-specific inhibitor p16(INK4), suggesting that plasmodial CDKs may be regulated by inhibitory proteins in vivo in a manner partially conserved with mammalian CDKs.","method":"In vitro kinase inhibition assay with recombinant CDK inhibitor proteins","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro assay with recombinant proteins, single study, no in vivo validation","pmids":["11700040"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2003,"finding":"Three novel P. falciparum cyclin-related proteins (Pfcyc-2, Pfcyc-3, Pfcyc-4) activate PfPK5 in vitro, as evidenced by their ability to stimulate histone H1 kinase activity in association with PfPK5. Additionally, RINGO (a non-cyclin CDK activator) also strongly activates PfPK5 in vitro.","method":"In vitro kinase activation assay with recombinant proteins, histone H1 kinase assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with multiple cyclin partners, single lab, no in vivo validation","pmids":["12869562"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2003,"finding":"The crystal structure of PK5 (PfPK5) was determined, representing the first structure of a P. falciparum protein kinase and the first CDK structure from a non-human source. The fold and mechanism of inactivation of monomeric CDKs are highly conserved. PfPK5 was co-crystallized with three ATP-competitive CDK inhibitors, revealing sequence differences from human CDKs within inhibitor binding sites that suggest selective inhibition is achievable.","method":"X-ray crystallography, co-crystallization with inhibitors","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure determination with multiple co-crystal structures, functionally validated inhibitor binding sites identified","pmids":["14604523"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2015,"finding":"PK5 (PfPK5) phosphorylates the N-terminal domain of PfORC1 (Origin Recognition Complex subunit 1) in vitro using recombinant proteins. This phosphorylation abolishes DNA-binding activity of PfORC1, leads to changes in its subcellular localization, and triggers proteasome-mediated degradation of PfORC1 in schizonts, as demonstrated using transgenic parasites expressing wild-type or phosphorylation-mutant forms of ORC1.","method":"In vitro kinase assay with recombinant proteins, transgenic parasite expression of WT and mutant ORC1, subcellular localization analysis, proteasome inhibitor experiments","journal":"Molecular microbiology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay combined with transgenic parasite validation using mutant proteins and defined phenotypic readouts, multiple orthogonal approaches","pmids":["26094711"],"is_preprint":false,"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":1998,"finding":"The CRK2 proteins of P. knowlesi and P. berghei are highly homologous to P. falciparum PfPK5. However, unlike PfPK5, a recombinant monomeric P. knowlesi CRK2 protein showed no kinase activity, and neither the P. knowlesi nor P. berghei CRK2 recombinant protein was able to complement a yeast cdc28ts mutant.","method":"Sequence analysis, recombinant protein expression, in vitro kinase assay, yeast complementation","journal":"Molecular and biochemical parasitology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — comparative negative result (no kinase activity for orthologs), single study, relevant as contrast to PfPK5 activity","pmids":["9803415"],"is_preprint":false,"attribution":[{"species":"Plasmodium knowlesi","strain":""},{"species":"Plasmodium berghei","strain":""}]}],"current_model":"PK5 (PfPK5) is a cyclin-dependent kinase homologue in P. falciparum that displays intrinsic kinase activity (phosphorylating substrates such as histone H1 and casein), is activated in vitro by cyclins (including the parasite's own Pfcyc-1 and human cyclin H/p25) but not by the parasite's own CDK-activating kinase Pfmrk, can autophosphorylate in the presence of cyclin, is inhibited by endogenous-type inhibitors such as p21(CIP1), is implicated in S-phase regulation during intra-erythrocytic development, and directly phosphorylates PfORC1 to abolish its DNA-binding activity, alter its subcellular localization, and promote its proteasomal degradation in schizonts; the crystal structure of PfPK5 has been solved and reveals a conserved CDK fold with inhibitor-binding site differences from human CDKs that can be exploited for selective drug design."},"narrative":{"mechanistic_narrative":"PK5 (PfPK5) is a cyclin-dependent kinase homologue of Plasmodium falciparum that functions in cell-cycle regulation during the intra-erythrocytic asexual stage, where it is implicated in the control of S-phase DNA synthesis [PMID:8143724, PMID:8943149]. Recombinant PfPK5 is an intrinsically active kinase that phosphorylates histone H1 and casein and is present at approximately constant cytosolic levels across asexual development [PMID:8143724]. Its activity is stimulated in vitro by cyclins — including the parasite cyclin homologue Pfcyc-1 and additional cyclin-related proteins (Pfcyc-2/3/4), the non-cyclin activator RINGO, and heterologous human cyclin H and p25 — and PfPK5 autophosphorylates in the presence of a cyclin, yet it is neither activated nor phosphorylated by the parasite CDK-activating kinase Pfmrk [PMID:10722743, PMID:12869562]. PfPK5 is negatively regulated by CDK-inhibitor-type proteins, being inhibited in vitro by human p21(CIP1) but not by the CDK4/6-specific p16(INK4) [PMID:11700040]. A direct substrate is the origin recognition complex subunit PfORC1: PfPK5-mediated phosphorylation of the ORC1 N-terminal domain abolishes its DNA-binding activity, alters its subcellular localization, and triggers proteasome-mediated degradation of ORC1 in schizonts, coupling PfPK5 activity to control of DNA replication licensing [PMID:26094711]. The crystal structure of PfPK5, the first for a P. falciparum kinase, reveals a conserved monomeric CDK fold with inhibitor-binding-site differences from human CDKs that permit selective ATP-competitive inhibitor design [PMID:14604523].","teleology":[{"year":1994,"claim":"Establishing whether PK5 is a genuine functional kinase was the first requirement; recombinant expression showed it is an active enzyme, defining it as a bona fide protein kinase rather than a pseudokinase.","evidence":"Recombinant expression in E. coli with in vitro kinase assays against casein and histone H1, plus antibody-based localization","pmids":["8143724"],"confidence":"Medium","gaps":["Physiological substrates not identified","In vitro activity not linked to a cellular process","Localization from a single antibody study without replication"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":1994,"claim":"Whether PfPK5 is functionally equivalent to yeast cdc2 was tested by complementation, but the assay was uninformative because the gene was not expressed in yeast.","evidence":"Yeast cdc2/cdc28 mutant complementation assay (negative, confounded)","pmids":["8143724"],"confidence":"Low","gaps":["Negative result confounded by lack of expression in yeast","No conclusion about cdc2 equivalence possible"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":1996,"claim":"To place PfPK5 in a cell-cycle context, its activity was correlated with S-phase and probed pharmacologically, indicating a role in DNA synthesis during nuclear division.","evidence":"Immunoprecipitation kinase assays from aphidicolin-blocked parasites, CDK-inhibitor (flavopiridol, olomoucine) treatment of cultures, immunolocalization","pmids":["8943149"],"confidence":"Medium","gaps":["Pathway placement rests on non-selective pharmacological inhibitors","No direct S-phase substrate identified at this stage","Inhibitor effects on DNA synthesis not proven to act through PfPK5 specifically"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2000,"claim":"The regulatory logic of PfPK5 activation was defined by reconstituting cyclin activation, showing it behaves as a CDK activated by cyclins including its own Pfcyc-1 but independent of the parasite CAK Pfmrk.","evidence":"In vitro kinase activation assays with recombinant human cyclin H/p25 and Pfcyc-1, autophosphorylation assay, negative test with Pfmrk","pmids":["10722743"],"confidence":"High","gaps":["Physiological activating cyclin in vivo not established","Whether autophosphorylation is activating or regulatory in the parasite unclear","In vivo relevance of Pfmrk independence untested"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2001,"claim":"Negative regulation of PfPK5 was probed, showing it is sensitive to CIP/KIP-type but not INK4-type inhibitors, implying partial conservation of CDK-inhibitor control.","evidence":"In vitro kinase inhibition assays with recombinant human p21(CIP1) and p16(INK4)","pmids":["11700040"],"confidence":"Medium","gaps":["No endogenous parasite CDK inhibitor identified","No in vivo validation of inhibitory regulation","Heterologous human inhibitors used as surrogates"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2003,"claim":"The repertoire of PfPK5 activators was broadened, showing multiple parasite cyclins and the non-cyclin activator RINGO can each stimulate the kinase in vitro.","evidence":"In vitro histone H1 kinase activation assays with recombinant Pfcyc-2/3/4 and RINGO","pmids":["12869562"],"confidence":"Medium","gaps":["Which activator operates in vivo is unresolved","No cellular validation of these activator pairings","Specificity among the cyclins not defined"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2003,"claim":"The structural basis of PfPK5 and its druggability was established by solving the first P. falciparum kinase structure, revealing a conserved CDK fold and inhibitor-site differences exploitable for selective inhibition.","evidence":"X-ray crystallography with co-crystallization of three ATP-competitive CDK inhibitors","pmids":["14604523"],"confidence":"High","gaps":["No cyclin-bound activated-state structure","Selectivity predictions not confirmed by cellular potency here","Structure of substrate-bound complex unavailable"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":2015,"claim":"A direct physiological substrate and mechanistic output was identified, linking PfPK5 activity to control of replication licensing via phosphorylation-triggered inactivation and degradation of PfORC1.","evidence":"In vitro kinase assay on recombinant PfORC1 N-terminal domain, transgenic parasites expressing WT and phospho-mutant ORC1, DNA-binding, localization, and proteasome-inhibitor experiments","pmids":["26094711"],"confidence":"High","gaps":["Whether ORC1 is the principal in vivo substrate unknown","Timing/coupling to the activating cyclin not resolved","Genetic requirement of PfPK5 for parasite viability not established here"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]},{"year":1998,"claim":"Comparison with orthologs distinguished PfPK5 behaviour, since P. knowlesi and P. berghei CRK2 homologues were catalytically inactive as monomers and did not complement yeast cdc28.","evidence":"Sequence analysis, recombinant expression, in vitro kinase and yeast cdc28ts complementation assays in P. knowlesi and P. berghei proteins","pmids":["9803415"],"confidence":"Low","gaps":["Negative ortholog results; not direct evidence about PF3D7_1356900","Monomeric inactivity may reflect missing activating partner","Functional divergence across species unresolved"],"attribution":[{"species":"Plasmodium knowlesi","strain":""},{"species":"Plasmodium berghei","strain":""}]},{"year":null,"claim":"Whether PfPK5 is genetically essential in the asexual cycle and which cyclin-substrate pairing governs its physiological S-phase function in vivo remains undetermined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No conditional knockout/knockdown of PF3D7_1356900 in the corpus","In vivo activating partner not defined","Substrate set beyond ORC1 not mapped"],"attribution":[{"species":"Plasmodium falciparum","strain":""}]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":[],"partners":["PFCYC-1 (CYCLIN ACTIVATOR, IN VITRO) [#3]","PFCYC-2 / PFCYC-3 / PFCYC-4 (CYCLIN ACTIVATORS, IN VITRO) [#5]","RINGO (NON-CYCLIN ACTIVATOR, IN VITRO) [#5]","HUMAN CYCLIN H AND P25 (HETEROLOGOUS ACTIVATORS, IN VITRO) [#3]","HUMAN P21(CIP1) (INHIBITOR, IN VITRO) [#4]","PFORC1 (SUBSTRATE) [#7]","PFMRK (DOES NOT ACTIVATE OR PHOSPHORYLATE PFPK5) [#3]"],"other_free_text":["PfPK5 is an intrinsically active CDK homologue that phosphorylates histone H1 and casein in vitro and autophosphorylates in the presence of a cyclin [#0, #3].","Activity is elevated in aphidicolin-blocked parasites and cell-cycle CDK inhibitors block DNA synthesis, placing PfPK5 in S-phase control [#2].","Phosphorylation of PfORC1 by PfPK5 abolishes ORC1 DNA-binding, alters its localization, and drives proteasomal degradation in schizonts, coupling the kinase to replication licensing control [#7].","The crystal structure shows a conserved monomeric CDK fold with inhibitor-binding-site differences from human CDKs supporting selective ATP-competitive inhibitor design [#6].","Orthologous CRK2 proteins of P. knowlesi and P. berghei were catalytically inactive as monomers and did not complement yeast cdc28, contrasting with active PfPK5 — a comparison, not evidence about PF3D7_1356900 itself [#8]."]}},"prefetch_data":{},"corpus_meta":[{"pmid":"15479470","id":"PMC_15479470","title":"Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote.","date":"2004","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15479470","citation_count":421,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"8143724","id":"PMC_8143724","title":"Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8143724","citation_count":95,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"10722743","id":"PMC_10722743","title":"Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10722743","citation_count":88,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"14604523","id":"PMC_14604523","title":"Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition.","date":"2003","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/14604523","citation_count":81,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"12930149","id":"PMC_12930149","title":"Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.","date":"2003","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12930149","citation_count":80,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"8943149","id":"PMC_8943149","title":"Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles.","date":"1996","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/8943149","citation_count":72,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["protein kinase 5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"22047078","id":"PMC_22047078","title":"Structural and evolutionary divergence of eukaryotic protein kinases in Apicomplexa.","date":"2011","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/22047078","citation_count":70,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["curated_ref"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"12869562","id":"PMC_12869562","title":"Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12869562","citation_count":61,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"19250824","id":"PMC_19250824","title":"Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.","date":"2009","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/19250824","citation_count":51,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"16513357","id":"PMC_16513357","title":"Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp.","date":"2006","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16513357","citation_count":49,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"12556199","id":"PMC_12556199","title":"Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.","date":"2003","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/12556199","citation_count":38,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"8844681","id":"PMC_8844681","title":"Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum.","date":"1996","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/8844681","citation_count":30,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"25111632","id":"PMC_25111632","title":"Chemical interrogation of the malaria kinome.","date":"2014","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25111632","citation_count":26,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["protein kinase 5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"7477105","id":"PMC_7477105","title":"Comparison of introns in a cdc2-homologous gene within a number of Plasmodium species.","date":"1995","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/7477105","citation_count":24,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["CRK2"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"11700040","id":"PMC_11700040","title":"Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11700040","citation_count":22,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"26094711","id":"PMC_26094711","title":"Regulation of Plasmodium falciparum Origin Recognition Complex subunit 1 (PfORC1) function through phosphorylation mediated by CDK-like kinase PK5.","date":"2015","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26094711","citation_count":19,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"27326764","id":"PMC_27326764","title":"Correlation between Cyclin Dependent Kinases and Artemisinin-Induced Dormancy in Plasmodium falciparum In Vitro.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27326764","citation_count":16,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"14629982","id":"PMC_14629982","title":"Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.","date":"2004","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/14629982","citation_count":15,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5","protein kinase 5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"38127294","id":"PMC_38127294","title":"Structure-based virtual screening against multiple Plasmodium falciparum kinases reveals antimalarial compounds.","date":"2023","source":"Molecular diversity","url":"https://pubmed.ncbi.nlm.nih.gov/38127294","citation_count":11,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"26780367","id":"PMC_26780367","title":"Regulation of DNA replication proteins in parasitic protozoans: possible role of CDK-like kinases.","date":"2016","source":"Current genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26780367","citation_count":9,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"33247522","id":"PMC_33247522","title":"Artificial Intelligence Applied to the Rapid Identification of New Antimalarial Candidates with Dual-Stage Activity.","date":"2021","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/33247522","citation_count":9,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"29924131","id":"PMC_29924131","title":"Synthesis and molecular modelling studies of pyrimidinones and pyrrolo[3,4-d]-pyrimidinodiones as new antiplasmodial compounds.","date":"2018","source":"Memorias do Instituto Oswaldo Cruz","url":"https://pubmed.ncbi.nlm.nih.gov/29924131","citation_count":9,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"30328274","id":"PMC_30328274","title":"In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.","date":"2018","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/30328274","citation_count":8,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PK5","protein kinase 5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"9803415","id":"PMC_9803415","title":"Characterisation of the Cdc2-related kinase 2 gene from Plasmodium knowlesi and P. berghei.","date":"1998","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/9803415","citation_count":6,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["CRK2","cdc2-related kinase 2","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"11312574","id":"PMC_11312574","title":"Primary structure of the Plasmodium vivax crk2 gene and interference of the yeast cell cycle upon its conditional expression.","date":"2001","source":"Experimental parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/11312574","citation_count":4,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["CRK2","PvCRK2"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"33190491","id":"PMC_33190491","title":"Application and Comprehensive Analysis of Neighbor Approximated Information Theoretic Configurational Entropy Methods to Protein-Ligand Binding Cases.","date":"2020","source":"Journal of chemical theory and computation","url":"https://pubmed.ncbi.nlm.nih.gov/33190491","citation_count":4,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["protein kinase 5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"37692342","id":"PMC_37692342","title":"Naturally occurring phenylethanoids and phenylpropanoids: antimalarial potential.","date":"2023","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/37692342","citation_count":4,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"14604516","id":"PMC_14604516","title":"Can mosquitoes be bitten? A new hope for anti-malarial drug design.","date":"2003","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/14604516","citation_count":2,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"40591878","id":"PMC_40591878","title":"Exploring Plant-Derived Natural Products Against Plasmodium falciparum Malaria Causative Agent by Targeting Protein Kinase 5: Insights Into Computational Approaches.","date":"2025","source":"Chemistry & biodiversity","url":"https://pubmed.ncbi.nlm.nih.gov/40591878","citation_count":1,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["protein kinase 5","PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false},{"pmid":"40019687","id":"PMC_40019687","title":"Gefitinib as an antimalarial: unveiling its therapeutic potential.","date":"2025","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40019687","citation_count":0,"is_preprint":false,"source_species":["Pf"],"role":"primary","match_terms":["PfPK5"],"competing_organism_flag":false,"competing_organism_match":"","competing_organism_only":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15815,"output_tokens":2687,"usd":0.043875,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8135,"output_tokens":4297,"usd":0.07405,"stage2_stop_reason":"end_turn"},"total_usd":0.117925,"stage1_batch_id":"msgbatch_011BPjN2BL33F8cJXD1r7V7T","stage2_batch_id":"msgbatch_01Qwg6vP7qxkpL6Gsc7tajsb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"PK5 (PfPK5) expressed in E. coli as a recombinant protein displays kinase activity against casein and histone H1 substrates. Western blotting with polyclonal antibody showed the kinase is located in the parasite cytosol and is present in approximately constant amounts throughout the intra-erythrocytic asexual reproductive stage.\",\n      \"method\": \"Recombinant protein expression in E. coli, in vitro kinase assay, Western blotting, subcellular fractionation\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — in vitro kinase assay and localization established in a single study with no replication\",\n      \"pmids\": [\"8143724\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"PK5 (PfPK5) failed to complement cdc2/cdc28 yeast mutants, though the gene was not expressed in yeast, leaving open the question of functional equivalence to cdc2.\",\n      \"method\": \"Yeast complementation assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — negative complementation result, single study, confounded by lack of expression in yeast\",\n      \"pmids\": [\"8143724\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PK5 (PfPK5) immunoprecipitated from aphidicolin-blocked parasites shows elevated kinase activity, suggesting involvement in S-phase regulation. Treatment of parasite cultures with CDK inhibitors flavopiridol and olomoucine (which inhibit PfPK5 in vitro at concentrations similar to other CDKs) markedly inhibited DNA synthesis during nuclear division cycles. Immunolocalization provided further evidence for a role in S-phase.\",\n      \"method\": \"Immunoprecipitation kinase assay from stage-specific parasites, cell-cycle inhibitor treatment, immunolocalization\",\n      \"journal\": \"Molecular and biochemical parasitology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — multiple methods in single study but indirect pathway placement via pharmacological inhibitors\",\n      \"pmids\": [\"8943149\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PK5 (PfPK5) is efficiently activated in vitro by heterologous human cyclin H and p25 (a cyclin-like molecule that activates human CDK5), but is neither activated nor phosphorylated by Pfmrk (the putative P. falciparum CDK-activating kinase). PfPK5 can autophosphorylate in the presence of a cyclin. A novel P. falciparum cyclin homologue, Pfcyc-1, activates recombinant PfPK5 in vitro with efficiency similar to human cyclin H and p25. Activated PfPK5 can be inhibited by chemical CDK inhibitors.\",\n      \"method\": \"In vitro kinase activation assays with recombinant proteins, autophosphorylation assay, chemical inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro activation with multiple partner proteins, autophosphorylation assay, negative result for Pfmrk, multiple orthogonal approaches in single study\",\n      \"pmids\": [\"10722743\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PK5 (PfPK5) is inhibited by heterologous human p21(CIP1) in vitro, but is not inhibited by the CDK4/6-specific inhibitor p16(INK4), suggesting that plasmodial CDKs may be regulated by inhibitory proteins in vivo in a manner partially conserved with mammalian CDKs.\",\n      \"method\": \"In vitro kinase inhibition assay with recombinant CDK inhibitor proteins\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro assay with recombinant proteins, single study, no in vivo validation\",\n      \"pmids\": [\"11700040\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Three novel P. falciparum cyclin-related proteins (Pfcyc-2, Pfcyc-3, Pfcyc-4) activate PfPK5 in vitro, as evidenced by their ability to stimulate histone H1 kinase activity in association with PfPK5. Additionally, RINGO (a non-cyclin CDK activator) also strongly activates PfPK5 in vitro.\",\n      \"method\": \"In vitro kinase activation assay with recombinant proteins, histone H1 kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with multiple cyclin partners, single lab, no in vivo validation\",\n      \"pmids\": [\"12869562\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The crystal structure of PK5 (PfPK5) was determined, representing the first structure of a P. falciparum protein kinase and the first CDK structure from a non-human source. The fold and mechanism of inactivation of monomeric CDKs are highly conserved. PfPK5 was co-crystallized with three ATP-competitive CDK inhibitors, revealing sequence differences from human CDKs within inhibitor binding sites that suggest selective inhibition is achievable.\",\n      \"method\": \"X-ray crystallography, co-crystallization with inhibitors\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure determination with multiple co-crystal structures, functionally validated inhibitor binding sites identified\",\n      \"pmids\": [\"14604523\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PK5 (PfPK5) phosphorylates the N-terminal domain of PfORC1 (Origin Recognition Complex subunit 1) in vitro using recombinant proteins. This phosphorylation abolishes DNA-binding activity of PfORC1, leads to changes in its subcellular localization, and triggers proteasome-mediated degradation of PfORC1 in schizonts, as demonstrated using transgenic parasites expressing wild-type or phosphorylation-mutant forms of ORC1.\",\n      \"method\": \"In vitro kinase assay with recombinant proteins, transgenic parasite expression of WT and mutant ORC1, subcellular localization analysis, proteasome inhibitor experiments\",\n      \"journal\": \"Molecular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay combined with transgenic parasite validation using mutant proteins and defined phenotypic readouts, multiple orthogonal approaches\",\n      \"pmids\": [\"26094711\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The CRK2 proteins of P. knowlesi and P. berghei are highly homologous to P. falciparum PfPK5. However, unlike PfPK5, a recombinant monomeric P. knowlesi CRK2 protein showed no kinase activity, and neither the P. knowlesi nor P. berghei CRK2 recombinant protein was able to complement a yeast cdc28ts mutant.\",\n      \"method\": \"Sequence analysis, recombinant protein expression, in vitro kinase assay, yeast complementation\",\n      \"journal\": \"Molecular and biochemical parasitology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — comparative negative result (no kinase activity for orthologs), single study, relevant as contrast to PfPK5 activity\",\n      \"pmids\": [\"9803415\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Plasmodium knowlesi\", \"strain\": \"\"}, {\"species\": \"Plasmodium berghei\", \"strain\": \"\"}]\n    }\n  ],\n  \"current_model\": \"PK5 (PfPK5) is a cyclin-dependent kinase homologue in P. falciparum that displays intrinsic kinase activity (phosphorylating substrates such as histone H1 and casein), is activated in vitro by cyclins (including the parasite's own Pfcyc-1 and human cyclin H/p25) but not by the parasite's own CDK-activating kinase Pfmrk, can autophosphorylate in the presence of cyclin, is inhibited by endogenous-type inhibitors such as p21(CIP1), is implicated in S-phase regulation during intra-erythrocytic development, and directly phosphorylates PfORC1 to abolish its DNA-binding activity, alter its subcellular localization, and promote its proteasomal degradation in schizonts; the crystal structure of PfPK5 has been solved and reveals a conserved CDK fold with inhibitor-binding site differences from human CDKs that can be exploited for selective drug design.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PK5 (PfPK5) is a cyclin-dependent kinase homologue of Plasmodium falciparum that functions in cell-cycle regulation during the intra-erythrocytic asexual stage, where it is implicated in the control of S-phase DNA synthesis [#0, #2]. Recombinant PfPK5 is an intrinsically active kinase that phosphorylates histone H1 and casein and is present at approximately constant cytosolic levels across asexual development [#0]. Its activity is stimulated in vitro by cyclins — including the parasite cyclin homologue Pfcyc-1 and additional cyclin-related proteins (Pfcyc-2/3/4), the non-cyclin activator RINGO, and heterologous human cyclin H and p25 — and PfPK5 autophosphorylates in the presence of a cyclin, yet it is neither activated nor phosphorylated by the parasite CDK-activating kinase Pfmrk [#3, #5]. PfPK5 is negatively regulated by CDK-inhibitor-type proteins, being inhibited in vitro by human p21(CIP1) but not by the CDK4/6-specific p16(INK4) [#4]. A direct substrate is the origin recognition complex subunit PfORC1: PfPK5-mediated phosphorylation of the ORC1 N-terminal domain abolishes its DNA-binding activity, alters its subcellular localization, and triggers proteasome-mediated degradation of ORC1 in schizonts, coupling PfPK5 activity to control of DNA replication licensing [#7]. The crystal structure of PfPK5, the first for a P. falciparum kinase, reveals a conserved monomeric CDK fold with inhibitor-binding-site differences from human CDKs that permit selective ATP-competitive inhibitor design [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing whether PK5 is a genuine functional kinase was the first requirement; recombinant expression showed it is an active enzyme, defining it as a bona fide protein kinase rather than a pseudokinase.\",\n      \"evidence\": \"Recombinant expression in E. coli with in vitro kinase assays against casein and histone H1, plus antibody-based localization\",\n      \"pmids\": [\"8143724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological substrates not identified\", \"In vitro activity not linked to a cellular process\", \"Localization from a single antibody study without replication\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Whether PfPK5 is functionally equivalent to yeast cdc2 was tested by complementation, but the assay was uninformative because the gene was not expressed in yeast.\",\n      \"evidence\": \"Yeast cdc2/cdc28 mutant complementation assay (negative, confounded)\",\n      \"pmids\": [\"8143724\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Negative result confounded by lack of expression in yeast\", \"No conclusion about cdc2 equivalence possible\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"To place PfPK5 in a cell-cycle context, its activity was correlated with S-phase and probed pharmacologically, indicating a role in DNA synthesis during nuclear division.\",\n      \"evidence\": \"Immunoprecipitation kinase assays from aphidicolin-blocked parasites, CDK-inhibitor (flavopiridol, olomoucine) treatment of cultures, immunolocalization\",\n      \"pmids\": [\"8943149\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathway placement rests on non-selective pharmacological inhibitors\", \"No direct S-phase substrate identified at this stage\", \"Inhibitor effects on DNA synthesis not proven to act through PfPK5 specifically\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The regulatory logic of PfPK5 activation was defined by reconstituting cyclin activation, showing it behaves as a CDK activated by cyclins including its own Pfcyc-1 but independent of the parasite CAK Pfmrk.\",\n      \"evidence\": \"In vitro kinase activation assays with recombinant human cyclin H/p25 and Pfcyc-1, autophosphorylation assay, negative test with Pfmrk\",\n      \"pmids\": [\"10722743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological activating cyclin in vivo not established\", \"Whether autophosphorylation is activating or regulatory in the parasite unclear\", \"In vivo relevance of Pfmrk independence untested\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Negative regulation of PfPK5 was probed, showing it is sensitive to CIP/KIP-type but not INK4-type inhibitors, implying partial conservation of CDK-inhibitor control.\",\n      \"evidence\": \"In vitro kinase inhibition assays with recombinant human p21(CIP1) and p16(INK4)\",\n      \"pmids\": [\"11700040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No endogenous parasite CDK inhibitor identified\", \"No in vivo validation of inhibitory regulation\", \"Heterologous human inhibitors used as surrogates\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The repertoire of PfPK5 activators was broadened, showing multiple parasite cyclins and the non-cyclin activator RINGO can each stimulate the kinase in vitro.\",\n      \"evidence\": \"In vitro histone H1 kinase activation assays with recombinant Pfcyc-2/3/4 and RINGO\",\n      \"pmids\": [\"12869562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which activator operates in vivo is unresolved\", \"No cellular validation of these activator pairings\", \"Specificity among the cyclins not defined\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The structural basis of PfPK5 and its druggability was established by solving the first P. falciparum kinase structure, revealing a conserved CDK fold and inhibitor-site differences exploitable for selective inhibition.\",\n      \"evidence\": \"X-ray crystallography with co-crystallization of three ATP-competitive CDK inhibitors\",\n      \"pmids\": [\"14604523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cyclin-bound activated-state structure\", \"Selectivity predictions not confirmed by cellular potency here\", \"Structure of substrate-bound complex unavailable\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A direct physiological substrate and mechanistic output was identified, linking PfPK5 activity to control of replication licensing via phosphorylation-triggered inactivation and degradation of PfORC1.\",\n      \"evidence\": \"In vitro kinase assay on recombinant PfORC1 N-terminal domain, transgenic parasites expressing WT and phospho-mutant ORC1, DNA-binding, localization, and proteasome-inhibitor experiments\",\n      \"pmids\": [\"26094711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ORC1 is the principal in vivo substrate unknown\", \"Timing/coupling to the activating cyclin not resolved\", \"Genetic requirement of PfPK5 for parasite viability not established here\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Comparison with orthologs distinguished PfPK5 behaviour, since P. knowlesi and P. berghei CRK2 homologues were catalytically inactive as monomers and did not complement yeast cdc28.\",\n      \"evidence\": \"Sequence analysis, recombinant expression, in vitro kinase and yeast cdc28ts complementation assays in P. knowlesi and P. berghei proteins\",\n      \"pmids\": [\"9803415\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Negative ortholog results; not direct evidence about PF3D7_1356900\", \"Monomeric inactivity may reflect missing activating partner\", \"Functional divergence across species unresolved\"],\n      \"attribution\": [{\"species\": \"Plasmodium knowlesi\", \"strain\": \"\"}, {\"species\": \"Plasmodium berghei\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether PfPK5 is genetically essential in the asexual cycle and which cyclin-substrate pairing governs its physiological S-phase function in vivo remains undetermined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No conditional knockout/knockdown of PF3D7_1356900 in the corpus\", \"In vivo activating partner not defined\", \"Substrate set beyond ORC1 not mapped\"],\n      \"attribution\": [{\"species\": \"Plasmodium falciparum\", \"strain\": \"\"}]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0004693\", \"supporting_discovery_ids\": [0, 2, 3, 5, 7]},\n      {\"term_id\": \"GO:0004672\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0046777\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0016301\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0051726\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0006260\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"GO:0000082\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0043161\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"Pfcyc-1 (cyclin activator, in vitro) [#3]\",\n      \"Pfcyc-2 / Pfcyc-3 / Pfcyc-4 (cyclin activators, in vitro) [#5]\",\n      \"RINGO (non-cyclin activator, in vitro) [#5]\",\n      \"human cyclin H and p25 (heterologous activators, in vitro) [#3]\",\n      \"human p21(CIP1) (inhibitor, in vitro) [#4]\",\n      \"PfORC1 (substrate) [#7]\",\n      \"Pfmrk (does NOT activate or phosphorylate PfPK5) [#3]\"\n    ],\n    \"other_free_text\": [\n      \"PfPK5 is an intrinsically active CDK homologue that phosphorylates histone H1 and casein in vitro and autophosphorylates in the presence of a cyclin [#0, #3].\",\n      \"Activity is elevated in aphidicolin-blocked parasites and cell-cycle CDK inhibitors block DNA synthesis, placing PfPK5 in S-phase control [#2].\",\n      \"Phosphorylation of PfORC1 by PfPK5 abolishes ORC1 DNA-binding, alters its localization, and drives proteasomal degradation in schizonts, coupling the kinase to replication licensing control [#7].\",\n      \"The crystal structure shows a conserved monomeric CDK fold with inhibitor-binding-site differences from human CDKs supporting selective ATP-competitive inhibitor design [#6].\",\n      \"Orthologous CRK2 proteins of P. knowlesi and P. berghei were catalytically inactive as monomers and did not complement yeast cdc28, contrasting with active PfPK5 — a comparison, not evidence about PF3D7_1356900 itself [#8].\"\n    ]\n  }\n}","audit_flag":null,"strains":[{"strain":"Pf3D7","gene_id":"PF3D7_1356900","name":null,"product":"protein kinase 5","uniprot_acc":null,"chromosome":null,"start_pos":null},{"strain":"PbANKA","gene_id":"PBANKA_1133200","name":null,"product":"cdc2-related kinase 2","uniprot_acc":null,"chromosome":null,"start_pos":null},{"strain":"PkH","gene_id":"PKNH_1114600","name":null,"product":"Cell division control protein 2 homolog","uniprot_acc":null,"chromosome":null,"start_pos":null}],"gene_symbol":"PK5","evaluation":null}